Growth Factor

APOE4 alters brain immunity and cognition differently in females and males

by

A new study shows that APOE4 reshapes brain-linked immune and lymphatic pathways in strikingly different ways in females and males, with opposite cognitive effects when innate immunity is suppressed. Study: Sex-specific APOE4-dependent innate immunity regulates meningeal lymphatics, brain lipids, neuroinflammation, and cognition. Image Credit: ahmetmapush / Shutterstock In a recent study published in the journal Neuron, … Read more

Targeting IGF2BP2 improves anti-angiogenic therapy effectiveness in colorectal cancer

by

A recent study published in Engineering has shed light on a novel therapeutic target for improving anti-angiogenic treatment in colorectal cancer (CRC). The research, conducted by an international team of scientists from institutions including Sun Yat-sen University and The Chinese University of Hong Kong, identified the RNA N⁶-methyladenosine (m⁶A) reader insulin-like growth factor 2 mRNA-binding … Read more

Transcription factor HOXD13 drives melanoma growth and immune evasion

by

A molecule that helps regulate gene activity has also been shown to drive skin cancer growth and tumors’ ability to evade attack by the body’s immune system, a new study shows. Led by researchers at NYU Langone Health and its Perlmutter Cancer Center, the study showed that a key protein – the transcription factor HOXD13 … Read more

Palbociclib Improves Progression‑Free Survival in Double‑Positive Metastatic Breast Cancer: Results from the PATINA Phase 3 Trial

by

Archyde “`html Palbociclib Extends Progression-Free Survival in Aggressive Breast Cancer, Landmark Study Reveals Table of Contents 1. Palbociclib Extends Progression-Free Survival in Aggressive Breast Cancer, Landmark Study Reveals 2. Understanding the… You can read the full story here: Palbociclib Improves Progression‑Free Survival in Double‑Positive Metastatic Breast Cancer: Results from the PATINA Phase 3 Trial. Source link

Palbociclib improves progression-free survival in HER2 positive breast cancer

by

PrECOG, LLC, today announced the publication of final results from the pivotal phase 3 PATINA study in the New England Journal of Medicine (NEJM). The study evaluated whether adding palbociclib to anti-HER2 and endocrine therapy, following induction chemotherapy, could delay disease progression in patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) metastatic … Read more

Newly discovered survival pathway explains stubborn EGFR-driven lung cancers

by

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in a key gene called EGFR (epidermal growth factor receptor). In a study published in Science Advances, the researchers revealed a previously unknown survival mechanism and demonstrated that disrupting … Read more

Hormone FGF21 reverses fatty liver disease by signaling the brain

by

A pioneering research study published today in Cell Metabolism details how the hormone FGF21 (fibroblast growth factor 21) can reverse the effects of fatty liver disease in mice. The hormone works primarily by signaling the brain to improve liver function. University of Oklahoma researcher Matthew Potthoff, Ph.D., is the lead author of the study, which … Read more

New protein target could aid in muscle regeneration for degenerative conditions

by

For millions of people, losing muscle isn’t just about weakness; it’s about losing independence. Whether caused by Duchenne muscular dystrophy, aging or other degenerative conditions, muscle loss can make everyday activities – like walking, climbing stairs or even standing up – a daily struggle. But a recent discovery from researchers at the University of Houston … Read more

New targeted therapy shows early success in treating pediatric high-grade gliomas

by

An international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a first-ever clinical test of the targeted therapy avapritinib in pediatric and young patients with a form of high-grade glioma. They found that the drug, already FDA-approved for certain adult cancers, was generally safe and resulted in tumor reduction visible … Read more

Moffitt researchers discover new vaccine strategy for treating specific type of breast cancer

by

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen receptor-negative (HER2-positive, ER-negative) breast cancer and has shown encouraging results in a recent pilot study. Published in npj Breast Cancer, the study combined the HER2-targeting … Read more